38 related articles for article (PubMed ID: 2674283)
1. Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR).
Penna GO; Pontes MAA; Talhari S; Gonçalves HS; Talhari C; Pessoa AS; Pedroza V; Bührer-Sékula S; Stefani MMA; Penna MLF
Braz J Infect Dis; 2024; 28(2):103745. PubMed ID: 38697216
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
3. Adverse reactions induced by MDT/WHO (Rifampicin+Clofazimine+Dapsone) and ROM (Rifampicin+Ofloxacin+Minocycline) regimens used in the treatment of leprosy: a cohort study in a National Reference Center in Brazil.
Celestino IC; Antunes DE; Santos DF; Gimenes VL; de Souza FM; Goulart IMB
Front Pharmacol; 2024; 15():1346169. PubMed ID: 38515839
[No Abstract] [Full Text] [Related]
4. Clinical profile of leprosy patients: a prospective study.
Thakkar S; Patel SV
Indian J Dermatol; 2014 Mar; 59(2):158-62. PubMed ID: 24700934
[TBL] [Abstract][Full Text] [Related]
5. A challenging case of borderline lepromatous leprosy non-responsive to WHO-MDT: exploring approaches beyond WHO-MDT.
Sharma A; Parkhi M; Chhabra S; Narang T; Handa S; Dogra S
Trans R Soc Trop Med Hyg; 2024 May; ():. PubMed ID: 38695179
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of safety tool for ambulatory leprosy patients at risk of adverse outcome.
MacRae C; Kopalakrishnan S; Faust L; Klowak M; Showler A; Klowak SA; Boggild AK
Trop Dis Travel Med Vaccines; 2018; 4():1. PubMed ID: 29507748
[TBL] [Abstract][Full Text] [Related]
7. Leprosy-Insufficient Evidence for Monthly Multidrug Therapy.
Adler BL; Harnisch JP; Ochoa MT
JAMA Dermatol; 2024 May; ():. PubMed ID: 38809538
[No Abstract] [Full Text] [Related]
8. Leprosy-Insufficient Evidence for Monthly Multidrug Therapy-Reply.
Shi VJ; Poondru S; Rajpara A
JAMA Dermatol; 2024 May; ():. PubMed ID: 38809519
[No Abstract] [Full Text] [Related]
9. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):436-44. PubMed ID: 1474282
[TBL] [Abstract][Full Text] [Related]
10. Treatment of leprosy.
Kar HK; Gupta R
Clin Dermatol; 2015; 33(1):55-65. PubMed ID: 25432811
[TBL] [Abstract][Full Text] [Related]
11. Study of multidrug therapy in paucibacillary leprosy.
Kar PK; Sohi AS
J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
[TBL] [Abstract][Full Text] [Related]
12. A clinico-pathological study of multidrug regimen in paucibacillary leprosy.
Kar PK; Jha PK; Panayach JS; Snehi PS
Indian J Lepr; 1988 Apr; 60(2):235-41. PubMed ID: 3192972
[TBL] [Abstract][Full Text] [Related]
13. Paucibacillary leprosy: a comparative study of different schedules of multidrug therapy.
Ramakrishnan KR; Arora PN; Aggarwal SK; Ramachandra S
Indian J Lepr; 1988 Oct; 60(4):542-8. PubMed ID: 3253333
[TBL] [Abstract][Full Text] [Related]
14. Fixed duration MDT in paucibacillary leprosy.
Mathai R; George S; Jacob M
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):237-41. PubMed ID: 2071980
[TBL] [Abstract][Full Text] [Related]
15. A clinicopathological study of multidrug therapy in borderline tuberculoid leprosy.
Kar PK; Arora PN; Ramasastry CV; Dhaka RS
J Indian Med Assoc; 1994 Oct; 92(10):336-7. PubMed ID: 7822849
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
